Table I.
Patient statistics and metastasis.
| Case | Age, years | Surgery | Stage | ER | PgR | HER2 | Metastasis | CT | HT | RT | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 58 | Bp+Ax | 2A | + | + | + | Skin, lung, LN | 4 | 1 | 1 | 6 |
| 2 | 66 | Bt+Ax | 3A | + | + | - | Lung, liver, bone | 7 | 2 | 1 | 10 |
| 3 | 63 | Bt+Ax | 2B | + | + | - | Lung, LN | 0 | 2 | 0 | 2 |
| 4 | 45 | Bp+Ax | 2B | + | + | - | Bone, LN | 1 | 2 | 2 | 5 |
| 5 | 74 | Bt+SLN | 1 | + | + | - | Liver, bone, LN | 2 | 1 | 0 | 3 |
| 6 | 68 | (-) | 4 | + | - | - | Lung, liver, bone | 0 | 4 | 2 | 6 |
| 7 | 75 | (-) | 4 | + | - | - | Skin, lung | 3 | 0 | 1 | 4 |
| 8 | 49 | Bt+Ax | 4 | + | + | - | Lung | 0 | 2 | 0 | 2 |
| 9 | 66 | Bt+Ax | 2A | + | - | - | Lung, liver, bone | 4 | 2 | 1 | 7 |
| 10 | 71 | Bt+Ax | 3A | + | + | - | Skin, muscle | 0 | 0 | 0 | 0 |
Bp, partial mastectomy; Bt, total mastectomy; Ax, axillary lymph node dissection; SLN, sentinel lymph-node; ER, estrogen receptor; PgR, progesterone receptor; LN, lymph-node involvement; CT, chemotherapy; HT, hormone therapy; RT, irradiation therapy; HER2, human epidermal growth factor receptor type 2; (-), no surgical treatment; +, positive; -, negative.